|
SCHEDULE
13G |
|
|
Item 1(a) |
Name
of Issuer:
Oncocyte,
Inc. |
|
|
Item 1(b) |
Address
of Issuer’s Principal Executive Offices:
15
Cushing, Irving, California 92618 |
|
|
Item 2(a) |
Name
of Persons Filing:
This
Schedule 13G is being filed by and on behalf of (i) PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the “Trust”),
and (ii) Patrick W. Smith, as trustee of the Trust (each, a “Reporting Person” and collectively, the “Reporting
Persons”).
The
Reporting Persons have entered into a Joint Filing Agreement, dated October 9, 2024, a copy of which is incorporated by reference
as Exhibit A to this statement, pursuant to which the Reporting Persons agreed to file this Schedule 13G and any amendments hereto
jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Act of 1933, as amended. |
|
|
Item 2(b) |
Address
of Principal Business Office, or if None, Residence:
c/o
Patrick Smith, TTEE, 11445 E. Via Linda, Suite 2-411, Scottsdale, AZ 85259 |
|
|
Item 2(c) |
Citizenship:
The
Trust is formed under the laws of the State of Arizona. Patrick W. Smith is a citizen of the United States. |
|
|
Item 2(d) |
Title
of Class of Securities:
Common
Stock, no par value. |
|
|
Item 2(e) |
CUSIP
Number: 68235C107 |
|
|
Item 3 |
If
this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check
whether the person filing is:
Not
Applicable. |
|
|
Item 4 |
Ownership:
(a)
through (c):
The
information requested herein is incorporated by reference to the cover pages to this Schedule 13G. Percentage ownership is based
on 16,835,247 shares of Common Stock outstanding as of October 8, 2024, as provided by the Issuer.
The
shares reported herein are directly held by the Trust. As the trustee of the Trust, Patrick W. Smith may be deemed to beneficially
own the securities held by the Trust. Patrick W. Smith disclaims beneficial ownership of the shares reported herein except to the
extent of his pecuniary interest therein. |